Sharon Mates, Chairman and CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 240,246 shares at $74.46 ($18.0M) on 2024-08-23, disclosed to the SEC on 2024-08-23.
Scheduled sale ($18.0M) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.40 | 44,134 | $3.3M | 18.5% |
| 2 | $75.40 | 44,134 | $3.3M | 18.5% |
| 3 | $76.20 | 4,297 | $327K | 1.8% |
| 4 | $76.20 | 4,297 | $327K | 1.8% |
| 5 | $77.21 | 2,682 | $207K | 1.1% |
| 6 | $77.21 | 2,682 |
| $207K |
| 1.1% |
| 7 | $77.98 | 1,900 | $148K | 0.8% |
| 8 | $74.58 | 35,011 | $2.6M | 14.5% |
| 9 | $74.58 | 35,011 | $2.6M | 14.5% |
| 10 | $75.47 | 4,369 | $330K | 1.8% |
| 11 | $75.47 | 4,369 | $330K | 1.8% |
| 12 | $74.46 | 28,680 | $2.1M | 11.8% |
| 13 | $74.46 | 28,680 | $2.1M | 11.8% |
| Total | $75.03 avg | 240,246 | $18.0M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |
| ITCI | SELL | 2024-02-27 | $3.1M | — | Filing → |